SynthesisEuropean journal of medical research2025
Chronic urticaria and vitamin D supplementations: a systematic review.
Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East.The journal of allergy and clinical immunology. Global · 2026Article
- Vitamin D and Disease Perception Outcomes in a Cluster of Patients with High-Disease-Activity Chronic Spontaneous Urticaria.Journal of clinical medicine · 2026Article
- Colchicine in Contemporary Pharmacotherapy: Mechanistic Insights and Clinical Horizons.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic urticaria (CU), especially chronic spontaneous urticaria (CSU), is a long-term inflammatory skin condition marked by wheals and/or angioedema lasting over six weeks. Emerging evidence suggests a link between vitamin D deficiency and immune dysregulation associated with CU. Given vitamin D's immunomodulatory and anti-inflammatory effects, this review explores the therapeutic potential of vitamin D supplementation in CU management.
methodsA systematic review was conducted in accordance with PRISMA guidelines Electronic databases (PubMed, Scopus, Web of Science, and Google Scholar) were searched using relevant keywords. Studies included were randomized controlled trials (RCTs), case-control, and observational studies assessing serum vitamin D levels or supplementation in patients with CU. Data extraction and bias assessment were independently conducted using standardized tools: the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale.
resultsEleven studies involving 1,491 participants were included. Most studies demonstrated significantly lower serum 25(OH)D levels in patients with CU compared to healthy controls. Vitamin D supplementation, particularly in individuals with a deficiency, was associated with reductions in urticaria activity scores, symptom severity, and improved quality of life. High-dose regimens (e.g., 4,000 IU/day or 60,000 IU/week) appeared more effective. However, results varied due to heterogeneity in study design, dosage, and patient characteristics.
conclusionVitamin D supplementation may serve as a safe, accessible adjunct to standard CU treatment, particularly for those with confirmed deficiency. While evidence suggests potential benefits, further high-quality RCTs are needed to establish causality, optimal dosing, and long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.